World Continence Week 2022

Subject: the role of Sacral Neuromodulation (SNM) in the management of pelvic floor dysfunction, whereby Dr. Grilo will explain what Sacral Neuromodulation is, the indications and the results. Laura Thomas will talk about patient expectations, patient education and patient follow-up. Finally, a patient?? will say something about his/her experience (from diagnosis to SNM treatment).

Muvon Therapeutics have developed a highly innovative technology offering patients a minimally invasive, low-risk procedure (according to phase I data) in an outpatient setting. Potentially this procedure could prove a life changer and be long-lasting.

Tilla Care’s Cap Female Kit, including all the accessories (extension tube, lubricant gel, securement device and alcohol pads) has been developed by TillaCare Ltd., Israel. The UriCap is intended to be used as an external urine collection system for incontinent elderly women and can in many cases replace incontinence pads and invasive catheters.

Novuqare works together with healthcare professionals and patients on research and projects to initiate innovations and to develop clinically relevant healthcare solutions. Since their founding in 2011 they have developed long-term collaborations with several renowned healthcare partners. Their mission is to improve the care and health of patients by developing unique, innovative, medical-technological applications and services.

THURSDAY 23rd JUNE 2022 – 15.30-16.30 HRS (CET) Jiri Vermeulen, Wilfried Woesthuis, Minze Health and Prof. Stefan De Wachter, urologist at the University Hospital in Antwerp The automated bladder diary is a product intended to increase the patient compliance, usability and reliability of bladder diaries. Bladder diaries are an important tool ideally used throughout the […]

RNA therapeutics are a new class of medicines that have a broad applicability targeting disease relevant proteins. Proteins are large and complex molecules that play a critical role in the body’s capacity to be healthy. Currently, most approved drugs are small molecules and protein biologics, which can only target a very limited number of proteins or genes. Our RNA-based therapeutics can be used to selectively trigger protein overexpression or downregulation, for single or multiple protein targets with one RNA construct. This uncovers new therapeutic possibilities for previously undruggable targets.

On the launch of the “incontinence thematic Innovation Ecosystem”.